This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/art.41103 This article is protected by copyright. All rights reserved DR. COURTNEY BLAKE CRAYNE (Orcid ID : 0000-0002-5284-1587) DR. RANDY Q CRON (Orcid ID : 0000-0003-2661-3086) Article type : Full Length Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis Esraa M. Eloseily 1,2 , Peter Weiser 1 , Courtney, B. Crayne 1 , Hilary Haines 1 , Melissa L. Mannion 1 , Matthew L. Stoll 1 , Timothy Beukelman 1 , T. Prescott Atkinson 1 , and Randy Q. Cron 1 1,2 Esraa M. A. Eloseily MD, MRCPCH: University of Alabama School of Medicine, Birmingham, Alabama and Assiut University Children Hospital, Assiut, Egypt; 1 Peter Weiser MD, 1 Courtney B. Crayne, MD, MSPH; 1 Hilary Haines MD, Melissa L. Mannion MD, MSPH, Matthew L. Stoll MD, PhD, MSCS, Timothy Beukelman MD, MSCE, T. Prescott Atkinson MD, PhD, and Randy Q. Cron MD, PhD: University of Alabama School of Medicine. Dr. Cron received consulting fees from SOBI (Swedish Orphan Biovitrum) and serves as co-Principal Investigator on an investigator initiated clinical trial sponsored by SOBI. Dr. Beukelman serves as chair of a data safety monitoring board for SOBI. Address correspondence to Randy Q. Cron, MD, PhD, Children’s of Alabama, Department of Pediatrics, Division of Pediatric Rheumatology, Children’s of Alabama/University of Alabama at Birmingham, 1600 7th Avenue South, CPPN suite G10, Birmingham, AL 35233-1711. Tel: (205) 638-9438, FAX: (205) 996-9545, E-mail: rcron@peds.uab.edu.